IONIS PHARMACEUTICALS INC
ulefnersen
Fused in Sarcoma Amyotrophic Lateral Sclerosis
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for ulefnersen in Fused in Sarcoma Amyotrophic Lateral Sclerosis are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“Additional Phase 3 readouts from partnered programs: o Results from FUSION study of ulefnersen for Fused in Sarcoma (FUS) Amyotrophic Lateral Sclerosis (ALS) (Otsuka)”